Tianshu Pharmaceutical Selected to Build "Hubei Provincial CDMO R&D and Production Pilot Test Platform for High-end APIs and Pharmaceutical Intermediates"

Recently, the Hubei Provincial Department of Economy and Information Technology announced the 2025 list of provincial manufacturing pilot test platforms for cultivation and construction. The Hubei Provincial CDMO R&D and Production Pilot Test Platform for High-end APIs and Pharmaceutical Intermediates, undertaken by Hubei Tianshu Pharmaceutical Co., Ltd. ( Tianshu Pharmaceutical), was successfully selected into the list.

　　"Pilot test" refers to a transitional experiment that transforms new products in the trial production stage into the production process. Manufacturing pilot test is a key link in promoting the industrialization of scientific and technological achievements, and an important way to promote technological iteration, process improvement, and product innovation. Its core is to enable faster transformation of innovative achievements into real productive forces.

　　The CDMO R&D and Production Pilot Test Platform for High-end APIs and Pharmaceutical Intermediates built by Tianshu Pharmaceutical closely revolves around the company's overall product development concept of "R&D and innovation integration, pilot test incubation acceleration, and industrial empowerment improvement". It unblocks the intermediate link between R&D and industrialization supply services for API and pharmaceutical intermediate CDMO projects, builds a complete service system covering product R&D, pilot test, and industrial production, and continuously provides high-quality CRO/CDMO full-industry-chain services for domestic and foreign customers.